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ABSTRACT
Endometrial cancer is one of the most prevalent uterine malignancies. This disease occurs most-
ly in older women, frequently affected with other comorbidities. Hence, it is important to search 
for novel, less burdensome diagnostic modalities, enabling the objective assessment of the 
patient’s status and facilitating qualification to relevant risk groups prior to surgical treatment. 
The aim of this study was to verify the usefulness of CA125 and HE4 in the evaluation of endometrial cancer.
The study included 308 women treated at University Hospital No. 2 in Bydgoszcz. The study group included 
180 patients operated due to endometrial cancer. The control group included 128 women operated due 
to perineal statics disorders. The concentrations of tumour markers were measured with ELISA-based 
ready-to-use diagnostic kits.
Patients with endometrial cancer and healthy women differed significantly in terms of HE4 concentra-
tions (P = 0.001). The serum concentration of HE4 in stage I endometrial cancer patients was 
significantly higher (Me = 88.37 pM) than in healthy women (Me = 46.14) (P = 0.007). The anal-
ysis of ROC curves with the determination of the area under curve showed 66.7% sensitivity and 
78.1% specificity of HE4. AUC for HE4 amounted to 0.721 and was the highest of all markers. 
Our analysis revealed that HE4 is useful in the detection of endometrial cancer, while Human Epididymis 
Protein 4 can potentially be used for screening purposes. CA125 antigen, previously used in the diag-
nostic process, is useless or may possess limited usefulness. There is a need for further studies on larger 
populations of female patients.
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Introduction
Endometrial cancer is one of the most common uter-
ine malignancies. It is the sixth most common cancer in 
women in the world [1]. The incidence of endometrial 
cancer is higher in countries with high economic status, 
as compared with poorer countries. In the United States, 
the incidence rate is 42/100 k/year, while in Western 
Europe the incidence rate is 34/100  k/year. The oc-
currences in people above 45 years of age represent 
more than 90% of the cases and are cumulated mainly 
in two peaks: at 54–59 and 65–70 years of age [2, 3]. 
It has been observed that the disease develops in an 
increasing number of young women of reproductive 
age (5–8% of patients). Recent studies suggest an 
increase in the number of deaths due to endometrial 
cancer, despite a significant decline in mortality rates 
observed to date [4]. 
Up to 90% of cases of endometrial cancer are char-
acterised by early onset of symptoms, which allows 
an early diagnosis of the disease [5]. The diagnostics 
allowing the identification of the disease are based on 
histopathological analysis of the material obtained via 
fractional curettage of the uterine cavity and the cervical 
canal or via endoscopic methods. Due to the presence 
of the tumour mainly in elderly women, often burdened 
with additional diseases, it is important to seek less in-
vasive diagnostic techniques. Determining new, highly 
sensitive, and specific tumour markers appears to be 
one such method.
The markers known to date cannot be routinely 
used in the diagnostics of uterine cancer due to their 
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relatively low sensitivity and specificity, and the predic-
tive value of the tests that allow the quantification of 
these substances.
The proportion of cases of operable stage 1 endo-
metrial cancer is 75%. However, 20–30% of patients 
classified to FIGO (International Federation of Gynaecol-
ogy and Obstetrics) stage 1 are at high or medium risk 
of relapse related with infiltration of the uterine muscle, 
invasion of lymphatic vessels, and a high degree of 
differentiation [8, 9]. This group of patients may benefit 
most from markers that permit detection of early relapse 
and monitoring the response to the treatment used. 
At the same time, a sufficiently sensitive and specific 
marker can be used as a prognostic indicator before 
the planned surgical intervention in order to ensure the 
proper therapeutic decisions. 
It is important to search for a tumour marker to be 
used for screening in women at high risk of endome-
trial cancer, including those with Lynch II syndrome or 
the PTEN gene defect, as well as patients treated with 
tamoxifen or obese patients with diabetes. A sensitive 
marker is essential in the monitoring of patients with 
a high risk of relapse or a systemic form of endome-
trial cancer. Currently, the monitoring of patients after 
and during treatment is based mainly on the clinical 
assessment of symptoms and diagnostic imaging, 
which results in a late diagnosis of an already advanced 
disease [10]. 
Studies published to date suggest an increased 
expression of HE4 in endometrial cancer [11–13]. 
Moore, R.G et al. reported that the HE4 concentration 
is increased at all stages of endometrial cancer and 
is characterised by higher sensitivity in the detection 
of the tumour compared to CA125 (78.7% vs. 67.1%) 
[12–13]. Therefore, the aim of this study was to evalu-
ate the suitability of the quantification of the tumour 
markers HE4 and CA125 for the diagnostics of endo-
metrial cancer.
Material and methods
Permission to conduct this study was obtained 
from the Bioethics Committee of the Ludwik Rydygier 
Collegium Medicum of Nicolaus Copernicus University 
in Toruń (no. KB/248/2010). 
Study design and subjects
The study included 308 women who were patients in 
the Clinic of Obstetrics, Gynaecological Diseases, and 
Oncological Gynaecology of the J. Biziel University Hos-
pital no. 2 in Bydgoszcz in 2010–2011. Included were 
only postmenopausal women with the last menstrual 
period at least one year prior to the study.
The patients for each group were recruited sepa-
rately. The patients were divided into two groups. The 
study group consisted of 180 patients operated due 
to endometrial cancer diagnosed preoperatively in 
a histopathological examination. The control group 
consisted of 128  women operated due to perineal 
statics disorders. The diagnosis was based on a his-
topathological examination performed at the Institute 
of Pathomorphology of the J. Biziel University Hospital 
no. 2 in Bydgoszcz. The mean age of the patients diag-
nosed with cancer was 61 years (SD = 10.8), while the 
mean age of the patients from the control group was 
61 years (SD = 9.5). 
All women included in the study underwent a med-
ical history, gynaecological examination with rectal 
examination, and ultrasound examination. 
Medical history concerned the age, the date of the 
first and the last menstruation, the number of pregnan-
cies and deliveries, the occurrence of chronic diseases 
(diabetes, hypertension, cancer), and drugs (tamoxifen). 
The gynaecological examination included cytology, 
speculum examination, and bimanual pelvic examina-
tion. Ultrasonography was performed using standard 
transvaginal probes with a frequency range of 5-9 MHz.
Body mass index (BMI) was calculated based on 
the formula: BMI = weight [kg] / height [m2]
Hypertension was diagnosed when the value of 
systolic blood pressure was above 140 mmHg and the 
value of diastolic blood pressure was above 90 mmHg 
(as defined by the World Health Organisation).
Clinical diagnosis was based on histopathological 
examination of uterine cavities that were performed at 
the Department of Pathomorphology of the J. Biziel 
University Hospital no. 2 in Bydgoszcz.
Statistical analyses did not reveal any statistically 
significant differences between the compared groups.
Blood sampling
The examined material was blood serum obtained 
from fasting patients preoperatively by basilic vein punc-
ture. A volume of 10 ml was collected into sterile glass 
tubes without anticoagulant. In order to obtain blood 
serum, blood samples were centrifuged for 10 minutes 
at about 1500 ´ g. The obtained sera were stored at 
-80°C until the determination of markers was performed.
Methods and statistical analysis
The concentration of HE4 and CA125 in the blood 
serum of the women were determined using ready-to-
use ELISA test kits based on a sandwich immunoen-
zymatic system.
To determine the serum concentration of HE4, we 
used the HE4 EIA test from FUJIREBIO Diagnostics, 
Inc. (Gothenburg, Sweden), with a range of detection 
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of 15–900 pM. CA125 was quantified using ELISA tests 
from Demeditec Diagnostics GmbH (Kiel, Germany) 
with a range of detection of 0–500 U/ml.
Statistical analysis
Statistical analysis was performed using the statistical 
software STATISTICA 9.1 from StatSoft® and employed 
Shapiro-Wilk normality test and Student’s t-test for inde-
pendent quantitative variables with a distribution similar 
to normal. Other variables were assessed using the 
Mann-Whitney U test. The analysis of the qualitative vari-
ables was performed using the nonparametric chi-square 
test, and the results were presented in a contingency table 
with percentages calculated by columns. Differences at 
a significance concentration P < 0.05 were considered 
as statistically significant and marked. Multidimensional 
dependencies were shown in logistic regression models 
using independent variables of a dichotomous nature that 
were determined based on the cut-off values estimated 
in ROC analysis. The assessment of the diagnostic accu-
racy of the tumour markers was conducted on the basis 
of the producer’s reference values and our own data, 
including the 95% confidence interval of the arithmetic 
mean (95% CI). The sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV), and 
accuracy of the method were established. The presented 
ROC charts including the area under the curve (AUC) 
also proved helpful in the assessment of the diagnostic 
suitability of the markers.
Results
The patients were divided into two groups. The char-
acteristics of the investigated groups are given in Table 1.
The mean age of the patients diagnosed with 
cancer was 61  years (SD  =  10.8), while the mean 
age of the patients from the control group was 
61 years (SD  =  9.5). The difference between the 
two compared means was not statistically significant 
(P  =  0.897). Similarly, the investigated groups did 
not differ in terms of the time since the last menstrual 
period (P = 0.514 and P = 0.735, respectively), BMI 
(P  =  0.285), and the number of pregnancies and 
deliveries in the patients’ lifetimes (P  =  0.260 and 
P = 0.244, respectively). 
Statistically significant differences between the in-
vestigated groups were observed in the concentration of 
HE4 (P = 0.001), with medians of 96.7 pM and 46.1 pM 
in the group of women with endometrial cancer and in 
the healthy women, respectively. The obtained results 
are shown in Figure 1.
An analysis of the concentration of the tumour mark-
ers CA125 and HE4 in the blood serum of women with 
endometrial cancer and women from the control group 
was conducted. The median CA125 concentration was 
5.8 U/ml in the group of women with endometrial cancer 
and 5.2 U/ml in the group of women without cancer. 
The difference between the compared values was not 
statistically significant (P = 0.661) (Fig. 2). 
Among the 180 patients operated due to endometri-
al cancer, 140 (77.8%) were classified to stage 1 of clin-
ical advancement according to FIGO (2009), 24 (13.3%) 
were classified to stage 2, and 16 were classified to 
stages 3 and 4 (eight per stage, 4.4%). No statistical-
ly significant differences in the concentration of the 
tumour markers were observed between the group 
Table 1. Characteristics of the study groups
Cancer
N = 180
[M ± SD]
Control Group
N = 128
[M ± SD]
Age
(years)
61.1 ± 10.8 61.4 ± 9.5
FM
(age)
13.8 ± 1.7 14.1 ± 1.8
LM
(age)
49.8 ± 3.1 50.0 ± 3.1
BMI
(kg/m2)
30.0 ± 6.1 28.6 ± 4.8
Number of 
pregnancies
2.5 ± 1.3 2.8 ± 1.4
Number of births 2.2 ± 1.2 2.6 ± 1.4
M — mean; SD — standard deviation; FM — first menstruation; LM — 
last menstruation
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Figure 1. Serum concentrations of HE4 in endometrial 
cancer patients and in controls
204
Medical research journal 2019, vol. 4, no. 4
www.journals.viamedica.pl/medical_research_journal
Cancer
 
Control group
0
20
40
60
80
100
120
140
P = 0.294  
C
a
 1
2
5
 [
U
/m
l]
 
Median
25–75%
Min-Max
Figure 2. Serum concentrations of CA 125 in endometrial 
cancer patients and in controls
Table 2. Tumour marker concentration in patients with endometrial cancers representing FIGO stage I, higher stages 
of the FIGO classification, and in the controls
Markers Statistical 
parameter
FIGO
Control group
N = 128
Endometrial 
cancer group
N = 180
I
N = 140
II-IV
N = 40
CA125 
[U/ml]
Me
Q1
Q3
5.2
3.4
7.5
5.8
3.7
12.4
4.8
2.7
12.4
8.1
5.6
13.6
HE4 
[pM]
Me
Q1
Q3
46.1
31.2
76.3
96.7
51.8
134.2
88.4
44.6
125.8
122.5
87.9
211.6
FIGO — The International Federation of Gynaecology and Obstetrics; Me — median; Q1 Q3 — quartile
of women with stage  1 endometrial cancer and the 
groups with further stages of the disease according 
to FIGO (Tab. 2).
It was found that the blood serum concentration 
of HE4 was significantly higher in the patients with 
stage 1 endometrial cancer compared to the group of 
Table 3. Endometrial cancer detection rates depending on a cut-off value for the CA125 test
Serum concentration  
CA125
The occurrence of endometrial cancer Total
present absent
N % N % N
>= 29.6 U/ml 16 9 12 9 28
< 29.6 U/ml 164 91 116 91 280
Total 180 100 128 100 308
p = 0.742
healthy women (P = 0.007), with medians of 88.37 pM 
and 46.14 pM, respectively (Tab. 2).
The statistical significance of CA125 markers 
(P = 0.795) and HE4 (P = 0.873) was not found depend-
ing on the incidence of type I and type II endometrial 
carcinoma in groups N = 164, N = 16, respectively
Tumour marker concentration stratified according 
to the histopathological grade of endometrial cancer 
to two groups G1 (N = 36) and G2/G3 (N = 136). In 
statistical analysis of CA125 marker, the P-value was 
near-borderline significance (P = 0.101). Analysis of 
HE4 showed no statistical significance (P = 0.363).
An analysis of the effectiveness of endometrial cancer 
detection depending on the concentration of the tested 
marker was conducted. The adopted cut-off values were 
based on the reference values of the diagnostic tests from 
Demeditec Diagnostics GmbH (for CA125) and FUJIRE-
BIO Diagnostics, Inc. (for HE4). No statistical significance 
was found in the results of the assessment of cancer 
detection effectiveness relative to the reference values for 
CA125 and HE4. The results are shown in Table 3 and 4.
In the presented study, no correlation was observed 
between the concentration of CA125/HE4 at 95% CI 
and the effectiveness of endometrial cancer detection 
(P = 0.652 and P = 0.276, respectively).
High specificity of tumour markers with clearly un-
satisfactory sensitivity and low predictive value, positive 
and negative, causes the accuracy to be estimated at 
a concentration no greater than 60% (Tab. 5).
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AUC — area under curve 
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Figure 3. Area under the receiver operating characteristic 
(ROC-AUC) curve for HE-4 as a diagnostic marker of 
endometrial cancer
Table 4. Endometrial cancer detection rates depending on a cut-off value for the HE4 test
Serum concentration
HE4
The occurrence of endometrial cancer Total
present absent
N % N % N
>= 150 pM 40 22 16 13 56
< 150 pM 140 78 112 88 252
Total 180 100 128 100 308
p = 0.276
Table 5. Summary of diagnostic accuracy of the analysed tumour markers
Markers Criterion Sensitivity Specificity PPV NPV Accuracy
CA125 reference value (29.6 U/ml) 8.89% 90.63% 57.14% 41.43% 42.86%
95% CI (18.26 U/ml) 15.56% 90.63% 70.00% 43.28% 46.75%
HE4 reference value (150 pM) 22.22% 87.50% 71.43% 44.44% 49.35%
95% CI (141.62 pM) 22.22% 87.50% 71.43% 44.44% 49.35%
NPV — negative predictive value; PPV — positive predictive value
CA125 offers the best diagnostic usefulness with-
in the 95%  CI, reaching 90.63% specificity and 70% 
positive predictive value, with 15.56% sensitivity and 
a negative predictive value of 43.28%. The diagnostic 
accuracy for this cut-off value was 46.75%. 
The reference value for the HE4 test within the 
previously established 95% CI allows the detection of 
endometrial cancer with 22.22% sensitivity and 87.5% 
specificity, with a satisfactory positive predictive value of 
71.43%. The diagnostic accuracy of this tumour marker 
is up to 49.35%.
A ROC curve analysis was performed in order to 
assess the diagnostic value of the tumour markers. As-
sessing the blood serum HE4 concentration allowed 
determination of the presence of endometrial cancer 
with 66.7% sensitivity and 78.1% specificity, with ex-
tinction values above 80.487 pM. The area under the 
ROC curve for HE4 was 0.721, which indicated a good 
diagnostic value (Fig. 3).
The area under the ROC curve for CA125 indicat-
ed a lack of discriminative value of this parameter as 
a prognostic factor in the diagnostics of endometrial 
cancer (Fig. 4).
In a summary of the diagnostic value of the inves-
tigated markers based on the AUC of the ROC curves, 
HE4 obtained the highest sensitivity at 66.7% with 
78.1% specificity and a satisfactory positive predictive 
value (PPV). 
When comparing the logistic regression models 
in terms of the ability to detect endometrial cancer 
by the investigated tumour markers, the optimal 
model in the diagnostics of endometrial cancer from 
a statistical point of view is model  2 (P  =  0.0001) 
(Tab. 6).
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Directional coefficient = 0,71; 
AUC = 0,530 ± 0,066 
Suggested cut-off point 3,729 
AUC — area under curve 
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Figure 4. Area under the receiver operating characteristic 
(ROC-AUC) curve for CA 125 as a diagnostic marker of 
endometrial cancer
Table 6. P-value from the analysis of logistic regression 
models that describe the ability to detect cancer by the 
analysed markers. Dichotomous independent variables 
are associated with the cut-off points determined during 
analysis of the ROC curves
Chi2
P
Marker 1
P
Marker 2
P
Model 1 0.3437 CA125
0.3466
Model 2 0.0001* HE4
0.0004*
Model 3 0.0003* CA125
0.5545
HE4
0.0005*
*P < 0.05
Discussion 
Endometrial cancer produces symptoms at the early 
stages of clinical advancement, which improves the 
prognosis. However, due to the lack of a safe, nonin-
vasive screening method for detecting this cancer, it is 
reasonable to search for new substances, particularly 
useful for patients with increased risk, including people 
with severe obesity and diabetes, Lynch syndrome, 
PTEN gene defects, or women treated with tamoxifen. 
Quantification of tumour markers in the blood serum of 
women seems to be acceptable as a potential diagnos-
tic method for detecting endometrial cancer due to the 
low cost of the method, the possibility of repeating the 
test at any interval, as well as the safety and diagnostic 
usefulness of the method. The quantitative nature of the 
obtained result, although not conclusive in the diagnos-
tics of the disease, allows the clinical assessment to be 
more objective.
In this study, an analysis of the concentration of tu-
mour markers was conducted using the blood serum of 
female patients with endometrial cancer in comparison 
with the control group. The median HE4 concentra-
tion was higher in the cancer patients to a statistically 
significant degree (P  =  0.001), while CA125 did not 
demonstrate such a correlation (P  =  0.661). The 
HE4 concentration in the cancer group and in the 
healthy women were 96.7 and 46.1 pM, respectively. 
Similar values were reported by Moore, R.G. et al. 
(71.5 and 35.4 pM, respectively), as well as by Znang, 
A.M. et al. [13–14]. The authors confirmed the presence 
of higher concentrations of HE4 in cancer patients as 
well, using another diagnostic method [11–13, 15–16].
There are also many reports on the increased con-
centration of CA125 in the blood serum of women with 
endometrial cancer. According to some authors, only 
10–30% of women with endometrial cancer have in-
creased concentration of this glycoprotein in the blood, 
which is confirmed by our results [17–18]. However, 
many publications report significant differences in the 
concentration of CA125 in the blood serum of women 
with endometrial cancer compared to healthy individu-
als [19–22]. In this study, the median CA125 concen-
tration in the blood serum of cancer patients was only 
5.8 U/ml and was virtually comparable to the median 
concentration of CA125 in the blood serum of healthy 
individuals (5.2 U/ml). The cause of such low values of 
the CA125 concentration in the blood serum of the in-
vestigated group may be, e.g., the prevalence of women 
at an early stage of disease advancement. This was 
confirmed by Powell, J.L. et al., who obtained the cor-
rect values of the blood CA125 concentration in approx. 
87.7% of the cases of FIGO stage 1 and 2 disease [22]. 
On the other hand, Nicklin, J. et al. obtained medians 
of approx. 14 U/ml and observed statistically significant 
differences in the CA125 concentration in the blood 
serum of women with endometrial cancer and healthy 
individuals [23]. The findings of Powell, J.L. and the 
authors of this study are confirmed in a study conducted 
by Bignotti, E., who did not observe any statistically 
significant differences in the group of patients with 
stage 1 and 2 of clinical advancement and the G1 de-
gree of histopathological differentiation in comparison 
with healthy individuals [15]. The results demonstrate 
the limited usefulness of the antigen CA125 in detecting 
endometrial cancer.
An interesting issue considered in this study is the 
evaluation of the concentration of the investigated mark-
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ers in relation to the stage of clinical advancement ac-
cording to FIGO. The obtained statistical differences in 
the concentration of HE4 in the blood serum of healthy 
women and women with FIGO stage  1 endometrial 
cancer suggest possible usefulness of this marker 
in screening tests (P  =  0.007). Human Epididymis 
Protein 4, as the only one of the investigated markers, 
demonstrated a different concentration in the control 
group and in patients with FIGO stage 1 cancer. This 
correlation has also been described by Moore, R.G. 
et al. and Bignotti, E. [13, 15]. However, these results 
were not confirmed by Kalogera, E. et al. (P = 0.49) 
[12]. Differences in the published studies suggest the 
need for further research on this topic. 
Some authors have reported a statistically significant 
difference between the concentration of HE4 in the 
blood serum of patients with FIGO stage 1 endometrial 
cancer and those with further stages of the disease [12, 
15]. In this study, the analysis of the concentration of 
HE4 was performed either at FIGO stage 1 or at further 
stages [2–4] of clinical advancement. Due to the small 
size of the groups with further stages of clinical advance-
ment, patients with FIGO stages 2–4 were assessed 
together. As opposed to other authors, we observed 
no statistically significant difference in the marker con-
centration (P = 0.120); however, the median HE4 con-
centration at further stages of clinical advancement was 
higher (122.46 pM) compared to stage 1 according to 
FIGO (median = 88.37 pM).
The differences in the blood serum concentration of 
CA125 in women with FIGO stage 1 and further stages 
of clinical advancement were close to statistical signifi-
cance (P = 0.062). The presented results are consistent 
with reports by other researchers, which confirm the 
correlation of the CA125 concentration with increasing 
degree of clinical advancement [15, 18, 22, 24].
In the analysis of the concentrations of the investi-
gated markers in relation to the aetiopathogenetic type 
of endometrial cancer, the median marker concentration 
values established in the blood serum of women with 
either type I or type II cancer were higher than those 
found in healthy individuals. No statistically significant 
differences with respect to the blood serum concentra-
tion of CA125 and HE4 were observed between women 
with type I and type II endometrial cancer (P = 0.795; 
P = 0.873). However, the median CA125 concentration 
was higher in patients with type II disease.
The concentration of HE4 shows an opposite re-
lationship, in which the median concentration of this 
marker in oestrogen-dependent cancer is higher than 
in the hormone-independent type. However, it should 
be pointed out that the group of patients with type II 
cancer in this study was small, which justifies the need 
for continuing the research in a larger group of pa-
tients. Our results of the HE4 quantification in patients 
with type I and II endometrial cancer are confirmed in the 
study published by Kalogera et al. [12]. As for the other 
markers, the correlation of higher marker concentrations 
with type II cancer allowed the identification of patients 
with poor prognosis, requiring constant monitoring for 
a possible relapse of the disease and a plan for more 
aggressive treatment.
The comparison of the marker concentration in rela-
tion to the degree of histopathological differentiation of 
endometrial cancer revealed no statistically significant 
differences. A tendency of the CA125 and HE4 con-
centration to reach higher values in the blood serum 
of patients with G2 and G3 cancer was demonstrated, 
with CA125 being nearest to statistical significance.
A similar correlation was shown in the studies by 
Powell, J.L. et al. and Dvalishvili, I.  et al. [22, 25]. Dif-
ferences in the concentration of HE4 depending on 
the degree of histopathological differentiation were 
observed by Bignotti, E. et al. [15].
For a reliable assessment of the diagnostic useful-
ness of the investigated tumour markers, the diagnostic 
sensitivity and specificity were established in relation to 
the different cut-off values for a given marker. 
The first assessment regarded the predictive value 
and utilised the suggested upper limit of the reference 
values (> 95%  CI) used in the study of diagnostic 
tests based on the ELISA method. On the basis of 
the authors’ own observations, the 95% CI value was 
established in the investigated group of women, and 
the effectiveness of the investigated tumour markers 
in endometrial cancer detection was assessed in rela-
tion to the results obtained. The study estimated the 
predictive capacity of CA125 with a sensitivity as low 
as 8.89% and a specificity of 90.63%, with the cut-off 
value based on the reference value upper limit from the 
CA19-9 ELISA test by Demeditec Diagnostics GmbH, 
which was ≥ 29.6 U/ml. No correlation with cancer oc-
currence was observed above this value (P = 0.742). 
The low positive and negative predictive value resulted 
in an accuracy estimate of only 42.86%. A slightly higher 
accuracy was obtained for the ≥95% CI established in 
the authors’ own study. For concentrations ≥ 18.26 U/ml, 
the accuracy was 46.75%. The low sensitivity and NPV 
values cause this marker to be ineffective in the diagnos-
tics of endometrial cancer. Despite the unsatisfactory 
results obtained in the assessment of diagnostic useful-
ness, CA125 is used in clinical practice for monitoring 
patients with a high risk of relapse of the disease. It is 
also used for planning the extent of surgery. Values 
≥65 U/ml strongly correlate with the spread of the dis-
ease outside the uterus [26].
Very disappointing results were obtained in the 
assessment of the effectiveness of endometrial cancer 
detection with HE4. The marker considered as the best 
marker in the diagnostics and monitoring of the treat-
208
Medical research journal 2019, vol. 4, no. 4
www.journals.viamedica.pl/medical_research_journal
ment of endometrial cancer obtained only 49.35% ac-
curacy. The obtained sensitivity of 22.22% is clearly un-
satisfactory in the assessment of the test marker, while 
the specificity of 87.5% is lower compared to CA125.
The lack of established standards for HE4 prevented 
the assessment of the marker’s usefulness in detect-
ing endometrial cancer in relation to the cut-off value 
adopted for the population of healthy women. The 
attempts to establish the reference values performed 
to date have produced divergent results and have not 
taken into account the influence of many factors. A re-
cent study by Bolstad, N. et al. involving material from 
1591 women and men presents the correlation between 
the HE4 concentration and smoking status and age. 
The cut-off values cited by the authors are significantly 
lower than the reference value from the HE4 EIA test by 
FUJIREBIO Diagnostics, Inc. (~150 pM), as well as the 
values proposed by Molina, R. et al. (> 130 pM) and 
Lenhard M. et al. [27–29].
Due to the unsatisfactory results obtained in the 
assessment of the diagnostic usefulness of the investi-
gated tumour markers, and in order to further compare 
them, ROC curves were established on the basis of 
the extinction value distribution for each parameter. 
Cut-off values characterised by the highest diagnostic 
value were identified, and the assessment of the area 
under the curve (ROC-AUC) was performed in order to 
estimate the discriminative value of each parameter.
The cut-off value for HE4 was established at 
80.487  pM, which allowed the detection of endo-
metrial cancer with 66.7% sensitivity and 78.1% 
specificity above the established extinction value. 
The positive predictive value of 81% allowed the de-
tection of the disease based on a positive test result 
above the established cut-off value. When calculat-
ing the area under the ROC curve for HE4, a good 
discriminative value of this parameter was observed 
(ROC–AUC = 0.721). Moor, R.G. et al. and Kalogera, 
E. et al. obtained similar results of 0.79 and 0.67, 
respectively [12–13]. The differences between the 
individual studies may be due to the differences in 
the distribution of stages of clinical advancement in 
the investigated groups of patients.
The values obtained with CA125 allowed confirma-
tion of the presence of a cancerous disease with 75.6% 
sensitivity and a very low specificity of 34.4%. The cut-off 
value (3.729  U/ml) established in this study differed 
significantly from the results obtained by Kim, B.W. et 
al., who reported a value of 18.7 U/ml. Moreover, the au-
thors obtained a fairly good discriminative capacity for 
this parameter because the area under the ROC curve 
was 0.689 with 49.3% sensitivity and 83.1% specificity 
[30]. The observed differences may arise from the dif-
ferent distribution of the clinical status of the patients 
included in the study. 
In the present study, an analysis of the correlation 
between the concentration of tumour markers and the 
occurrence of endometrial cancer was also performed. 
For this purpose, three logistic regression models 
with different combinations of the tested substances 
were established and assessed. Model 3, which took 
into account the influence of CA125 and HE4 on the 
detection of cancer, was characterised by a lower 
predictive capacity than the single-component mod-
el 1 (P = 0.0003 vs. 0.0001), which confirms the lack of 
any advantage of combined CA125 and HE4 determi-
nation in the diagnostics of endometrial cancer. Other 
researchers have also attempted similar analyses and 
obtained data suggesting an advantage of combined 
CA125 and HE4 determination over the assessment of 
single markers [13].
To conclude, the obtained results confirm that 
HE4 is the most sensitive and specific marker for the 
early detection of patients with endometrial cancer, as 
compared with CA125, which is commonly used in the 
monitoring of patients with endometrial cancer. How-
ever, the numerous discrepancies that are still observed 
in the assessment of the usefulness of the tumour mark-
ers indicate the need for further research involving larger 
groups and careful conclusions with reference to the 
established cut-off values for the healthy population.
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